We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Icagen Announces Initiation of Phase I Study for the Treatment of Epilepsy
News

Icagen Announces Initiation of Phase I Study for the Treatment of Epilepsy

Icagen Announces Initiation of Phase I Study for the Treatment of Epilepsy
News

Icagen Announces Initiation of Phase I Study for the Treatment of Epilepsy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Icagen Announces Initiation of Phase I Study for the Treatment of Epilepsy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Icagen, Inc. has announced the initiation of a Phase I study of ICA-105665, a small molecule compound for the treatment of epilepsy.

ICA-105665 is an activator of certain subtypes of KCNQ ion channels for the potential treatment of a variety of neuroexcitability disorders such as epilepsy and pain. These channels underlie a potassium current called the M-current, which is important in the regulation of the resting potential and electrical firing of certain nerve cells.

Mutations in a specific subtype of KCNQ channels have been linked to an inherited seizure disorder, which provides genetic validation for this approach.

In preclinical studies, ICA-105665 has demonstrated activity in models predictive of efficacy for the treatment of partial seizures, generalized seizures and treatment-resistant seizures.

In addition, ICA-105665 has also been shown to have activity in certain preclinical models of neuropathic and inflammatory pain. In preclinical studies conducted to date, this compound has demonstrated a favorable safety and toxicity profile, the company says.

ICA-105665 is administered orally and is intended to be developed as a chronic therapy for patients with epilepsy and potentially other disorders characterized by abnormal neuronal excitability.

The initial Phase I clinical trial is a double-blind, placebo controlled single dose ascending study in healthy male volunteers designed to assess the safety, tolerability and pharmacokinetics of the compound. Provided that data from this study are supportive, a subsequent study will assess the tolerability and pharmacokinetics of multiple doses.

Advertisement